IMR Press / EJGO / Volume 27 / Issue 1 / pii/2006112

European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with S.O.G.

Original Research

C-kit overexpression in neuroendocrine small cell carcinoma of the uterine cervix

Show Less
1 Department of Obstetrics and Gynecology, Jichi Medical School, Kawachi, Tochigi, Japan
2 Department of Obstetrics and Gynecology, School of Medicine, Kitasato University, Kitasato, Sagamihara, Japan
3 Department of Gynecology, Omiya Medical Center, Jichi Medical School, Omiya, Saitama, Japan
Eur. J. Gynaecol. Oncol. 2006, 27(1), 53–55;
Published: 10 February 2006

Purpose of investigation: Neuroendocrine small cell carcinoma of the uterine cervix (NESCC) grows aggressively, and is resis­tant to anticancer agents and radiation, having an extremely poor prognosis. The incidence of c-kit proto-oncogene overexpression is high in gastrointestinal stromal tumors (GISTs) and small cell lung cancer, and tyrosine kinase inhibitors have been used effec­tively to treat GISTs. Few studies have investigated whether c-kit is overexpressed in NESCC. To investigate whether NESCC can be a target for molecular targeted therapy with tyrosine kinase inhibitors, we examined the expression of c-kit in this tumor. Methods: Twenty-one NESCCs were examined for c-kit expression by immunohistochemical staining using the labeled strepta­vidin-biotin complex (LSAB) method. The expression of c-kit was regarded as positive (overexpression) and negative when the membrane and cytoplasm of more or less than 25%, respectively, of tumor cells were stained. Results: Nine NESCCs (43%) were c-kit-positive (overexpression). No difference in age or clinical stage was noted. No differ­ence in prognosis was observed between the c-kit-positive and -negative patients. Conclusion: The incidence of c-kit overexpression was high in NESCC; therefore, the patients with this tumor may become a future target for molecular-targeted therapy with tyrosine kinase inhibitors.

Neuroendocrine small cell carcinoma
Uterine cervix
Back to top